RTP Mobile Logo
Oncology Grand Rounds Series: Part 2 — Gastrointestinal Cancers (Webinar Video Proceedings)
Released July 2020

Proceedings from the second in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Melony Avella-Howell, Dr Wells A Messersmith, Dr Philip A Philip and Ms Tammy Triglianos. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastrointestinal (GI) cancers.

    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with GI cancers.


    • Apply available research data to the therapeutic and supportive care of patients with colorectal cancer (CRC), gastric cancer and hepatocellular carcinoma (HCC).
    • Communicate to patients with advanced HCC the benefits and risks of approved multikinase inhibitor regimens and emerging approaches with combined immune checkpoint inhibitors and anti-angiogenic agents.
    • Recognize the significance of biomarker status (eg, microsatellite instability, mismatch repair deficiency, PD-L1 expression, BRAF mutation) and tumor location in patients with CRC or gastric or gastroesophageal junction cancer, and use this information to counsel them about evidence-based options for systemic treatment.
    • Describe the clinical indications, benefits and toxicities associated with current and recently approved systemic therapies in the management of metastatic CRC (mCRC).
    • Appraise the rationale for and clinical data with immune checkpoint inhibitors and novel antimetabolites in the treatment of gastroesophageal cancer.
    • Develop a plan to manage the side effects associated with available and recently approved systemic therapies in order to support quality of life and continuation of treatment for patients with GI cancers.

    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CNE credit is no longer available for this issue

    CNE credit is no longer available for this issue

    This CNE activity consists of an audio component.
    CNE credit is no longer available for this issue

    This CNE activity consists of a video component.
    CNE credit is no longer available for this issue

    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Melony Avella-Howell, NP
    Aurora, Colorado

    No financial interests or affiliations to disclose.

    Wells A Messersmith, MD
    Professor and Head, Division of Medical Oncology
    Associate Director for Translational Research
    University of Colorado Cancer Center
    Aurora, Colorado

    Contracted Research: Aduro Biotech, ALX Oncology, AstraZeneca Pharmaceuticals LP, BeiGene, D3 Pharma, Gossamer Bio, Immunomedics Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics, QED Therapeutics.

    Philip A Philip, MD, PhD, FRCP
    Kathryn Cramer Endowed Chair in Cancer Research
    Professor of Oncology and Pharmacology
    Leader, GI and Neuroendocrine Oncology
    Karmanos Cancer Institute
    Wayne State University
    Detroit, Michigan

    No financial interests or affiliations to disclose.

    Tammy Triglianos, RN, MS, ANP-BC, AOCNP
    GI Oncology Nurse Practitioner
    Lineberger Comprehensive Cancer Center
    The University of North Carolina Division of Oncology
    Department of Medicine, University of North Carolina
    Chapel Hill, North Carolina

    No financial interests or affiliations to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

    RTP CNE (NCPD) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech, a member of the Roche Group, and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: July 2020
    Expiration date: July 2021

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):